Troponin
0
Maynard Paton | BIOVENTIX: Record H1 2024 Reveals Profit Up 15% Despite Slowing Troponin Growth As Encouraging Alzheimer’s Work Attracts ‘Significant Attention’ And Research-Test Availability Through Quanterix
0

Maynard Paton | BIOVENTIX: Record H1 2024 Reveals Profit Up 15% Despite Slowing Troponin Growth As Encouraging Alzheimer’s Work Attracts ‘Significant Attention’ And Research-Test Availability Through Quanterix

22 October 2024By Maynard Paton H1 2024 results summary for Bioventix (BVXP): A record H1, showing revenue up 13%, profit up 15% and the ...

admin admin May 29, 2025
READ MORE +
0
Maynard Paton | BIOVENTIX: £155k R&D Revenue And Commencement Of ‘Large-Scale Production’ Signal Increasing Alzheimer’s Success After Troponin Error Creates Below-Expectations FY 2024 And Leaves Dividend Yield Exceeding 5%
0

Maynard Paton | BIOVENTIX: £155k R&D Revenue And Commencement Of ‘Large-Scale Production’ Signal Increasing Alzheimer’s Success After Troponin Error Creates Below-Expectations FY 2024 And Leaves Dividend Yield Exceeding 5%

04 March 2025By Maynard Paton FY 2024 results summary for Bioventix (BVXP): A record FY, showing revenue up 6% and profit up 5%, although the 3p ...

admin admin March 14, 2025
READ MORE +
Som2ny Network
Logo
Register New Account
Compare items
  • Total (0)
Compare
0
Shopping cart